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Abstract
Purpose We hypothesized that due to its specific characteristics, the CasperTM RX carotid stent (CP) might be particularly
suitable for venous sinus stenting (VSS) in patients with idiopathic intracranial hypertension (IIH). To test this theory, we
compared it to the commonly used Precise Pro RXTM stent (PP).
Methods A total of 15 patients with IIH (median age 28.7 years) were reviewed retrospectively. Technical aspects as well
as periinterventional and postinterventional complication rates were examined in patients treated with CP (n= 10) and the
PP (n= 5). Improvements in cerebrospinal fluid opening pressure (CSF OP), transstenotic pressure gradient (TSPG) and
clinical symptoms were also assessed. Results are shown as percentages and respective P-values.
Results Stent delivery was easier and more successful with the CP than the PP (difficult/failed stent delivery 0.0%
versus 57.1%). No severe peri- or postinterventional complications or instances of in-stent thrombosis and/or stenosis were
observed during follow-up. Improvement of CSF OP and TSPG immediately after VSS as well as at 6-month follow-up
were comparable between the CP and PP groups. Both groups showed substantial and similar decreases in intensity and
frequency of headache. Almost all patients with other IIH-related symptoms showed either improvement or complete
resolution of the symptoms after VSS. All patients who were available for interview (n= 12/15) reported a substantial
improvement in quality of life.
Conclusion A VSS using the CP seems to be safe and effective. The CP may reduce the risk of difficult or failed stent
delivery in patients with challenging intracranial venous anatomy.
Keywords Idiopathic intracranial hypertension · Venous sinus stenting · Venous sinus stenosis · Cerebrospinal fluid
opening pressure · Stent delivery
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Abbreviations
CP CasperTM RX stent
CSF OP Cerebrospinal fluid opening pressure
DSA Digital subtraction angiography
GA General anesthesia
IIH Idiopathic intracranial hypertension
LA Local anesthesia
PP Precise Pro RXTM stent
TSPG Transstenotic pressure gradient
VSM Venous sinus manometry
VSS Venous sinus stenting
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Introduction
Idiopathic intracranial hypertension (IIH) is a relatively
rare disease mainly affecting obese women of childbear-
ing age (12–20 per 100,000 people per year in this group
[1]). Patients with IIH often exhibit a series of chronic
symptoms, such as moderate to severe headache, nau-
sea/vomiting, pulse synchronous tinnitus, photophobia/
phonophobia, diplopia and other visual disturbances (e.g.
obscuration, visual field defects) [2]. The increased in-
tracranial pressure observed in patients with IIH may lead
to permanent damage of the optic nerve and fulminant
vision loss [2]. Venous sinus stenting (VSS) has emerged
as a promising and efficient treatment alternative for IIH
patients whose condition is not improved by conservative
treatment and who demonstrate a functionally relevant ve-
nous sinus stenosis [3–9]; however, device delivery may
be challenging owing to the tortuosity of the transverse
and sigmoid sinuses, the high degree of stenosis, the an-
gle of the stenotic segment, small venous channels within
the sinus, arachnoid granulations, fibrous trabeculae or
the presence of a cortical vein draining into the dural
venous sinuses, which are frequently observed in IIH pa-
tients [10–13]. Forced device maneuvers can lead to severe
hemorrhagic complications including avulsion of cortical
veins and dissection or perforation of the sinus [14–16].
Since dedicated stent systems for this indication are not
available VSS is often performed by off-label application
of carotid stents [17]. The Casper RXTM (CP) stent system
(Casper RXTM, Microvention, Terumo, Tustin, CA, USA)
is a self-expanding, braided, nitinol stent with a dual-layer
micromesh design approved for carotid artery stenting. The
stent design is aimed to improve coverage, flexibility, con-
formability and wall apposition of the device, which should
lower the risk of periinterventional stroke during carotid
artery stenting procedures. We aimed to examine whether
these particular stent characteristics provide a technical ad-




The clinical and neurointerventional data presented in this
study were collected by reviewing medical records as well
as interviewing IIH patients who underwent VSS at Bern
University Hospital between October 2016 and April 2020.
The inclusion criteria were as follows: (1) final diagnosis of
IIH according to the modified Dandy criteria [19], (2) con-
firmation of a functionally relevant venous sinus stenosis
and (3) VSS performed. A venous sinus stenosis was con-
sidered functionally relevant if the transstenotic pressure
gradient (TSPG) was ≥4mmHg. Patients were regarded as
eligible for VSS if they were deemed refractory to conser-
vative treatment by the treating physicians or treatment had
to be stopped owing to side effects. Emergency VSS was
performed in cases of sudden and severe vision impairment
in conjunction with a functionally relevant venous sinus
stenosis confirmed with venous sinus manometry. General
consent was obtained from all 15 patients. This study was
approved by the local ethics committee.
Analysis of Clinical Information
Baseline demographics and clinical information, such as
age, sex, arterial hypertension, diabetes mellitus and obe-
sity (including body mass index) were gathered. The IIH-
related symptoms that were present prior to VSS, such as
headache [20] (intensity according to the visual analogue
scale, VAS 0–10 and frequency per week), tinnitus of any
kind, phonophobia and photophobia, nausea and/or eme-
sis, diplopia and other subjective visual disturbances (e.g.
transient visual obscuration, blurred vision) were also doc-
umented. Patients who experienced headaches of more than
one type in terms of severity, development, localization and
expansion were evaluated according to the instructions pro-
vided in the supplementary form A. The time from symp-
tom onset to first treatment as well as the duration of con-
servative treatment were documented. Finally, the presence
of papilledema and the cerebrospinal fluid opening pressure
(CSF OP) prior to VSS was recorded.
DSA and Venous Sinus Manometry
Venous sinus stenosis was diagnosed on digital subtraction
angiography (DSA) and then quantified with venous sinus
manometry (VSM) with the patient under local anesthesia
(LA). After establishing a transfemoral arterial and venous
access, a 6F guiding catheter was positioned in the jugular
bulb while the diagnostic catheter was placed in the ipsi-
lateral carotid artery. A VSM was then performed by navi-
gating a 0.027inch microcatheter through the venous sinus
and measuring the TSPG as described by Fargen et al. [21].
Venous Sinus Stenting
Patients eligible for VSS were administered 100mg/day as-
pirin and 75mg/day clopidogrel starting at least 5 days prior
to treatment. The DSA and VSM were repeated immedi-
ately prior to VSS with the patient under general anesthesia
(GA). The VSS was performed according to institutional
protocols and in accordance with the recommendation
published by Fargen et al. [22]. We used a standardized
endovascular access approach in all interventions. Venous
K
Casper Stent in Idiopathic Intracranial Hypertension
Table 1 Patient demographic characteristics and comorbidities. Data are expressed as percentages (n) or median (interquartile range 25–75%)
Data available for %
(n)
All patients (n= 15) CasperTM RX stent
(n= 10)
Precise Pro RXTM stent
(n= 5)
P-value
Age (years) 100% (15/15) 28.7 (24.0–41.5) 27.5 (22.33–37.23) 34.7 (25.45–50.8) 0.310
Sex (female, %) 100% (15/15) 100% (15) 100% (10) 100% (5) *
Comorbidities
Diabetes mellitus 100% (15/15) 20.0% (3) 10.0% (1) 40.0% (2) 0.242
Arterial hyperten-
sion
100% (15/15) 26.7% (4/15) 20.0% (2) 40.0% (2) 0.560
Body mass index 100% (15/15) 30.61 (25.71–34.96) 29.31 (25.63–34.78) 31.71 (26.01–41.90) 0.440
Obesity 100% (15/15) – – – 1.000
None – 13.3% (2/15) 10.0% (1) 20.0% (1) –
Moderate – 33.3% (5/15) 40.0% (4) 20.0% (1) –
Severe – 53.3% (8/15) 50.0% (5) 60.0% (3) –
* No p-value as only one variable is present
access was gained through the right common femoral vein
by inserting an 8F 25cm sheath (Radifocus® Introducer II,
Terumo, Tokyo, Japan). Then, an 8F guiding catheter
(Guider SoftipTM, Boston Scientific, Marlborough, USA;
Neuron MAXTM 088, Penumbra, Almeda, CA, USA) was
advanced as distally as possible into the ipsilateral internal
jugular vein or even the sigmoid sinus if possible. If stent
delivery was not possible by this monoaxial approach (e.g.
because of increased resistance and loading of the system),
the stent was delivered through an additional intermediate
catheter (Vasco +35, BALT, Montmorency, France; 6F
Sofia, Microvention, Tustin, USA), which was advanced
as distally as possible in order to achieve better pusha-
bility and deliverability. A long-braided sheath (8F Super
Arrow-Flex PSI set 80cm, Arrow International, Reading,
PA, USA) was introduced into the internal jugular vein
to further increase proximal stability, if necessary. The
decision on which stent to use was not randomized and
was made by the attending neurointerventionalist based on
the patient’s intracranial venous anatomy and the physi-
cian’s personal experience. The difficulty of stent delivery
was assessed retrospectively by a neurointerventionalist
(P.M.) with 12 years of experience after reviewing the DSA
images and the corresponding neurointerventional report.
Stent delivery was classified as easy in cases of monoaxial
access suggesting minimal loading of the system and/or no
mention of difficulties in the interventional report, as dif-
ficult in the case of a biaxial access using an intermediate
catheter and/or a long-braided sheath suggesting increased
loading of the system and/or mention of difficulties in the
interventional report or as failed if stent delivery could
not be performed using the initial endovascular approach.
The number of maneuvers required for successful stent
delivery were documented. Balloon-assisted dilatation after
stent deployment was performed in cases of residual steno-
sis, which was considered relevant if the TSPG remained
≥4mmHg. At the end of the procedure, DSA and VSM
were repeated to screen for periprocedural complications
and to compare preinterventional and postinterventional
transstenotic pressure values. All patients were monitored
in an intermediate care unit for a minimum of 24h after
VSS before being transferred to the neurology ward. As-
pirin, 100mg/day, was continued lifelong and clopidogrel,
75mg/day, for 6 months after VSS.
Stent Systems
All patients were treated with either the CP or the Precise
Pro RXTM stent (PP). The PP (CardinalHealth, Cordis, Santa
Clara, CA, USA) is a self-expanding, laser-cut nitinol stent
with a single-layer, V-pattern open-cell design, developed
for the treatment of carotid artery stenosis. According to the
literature, it is one of the stent devices most commonly used
off-label for VSS in patients with IIH [17]. Compared to the
CP, the open-cell V-segments in the PP have a larger strut
size. Although the single-layer, open-cell design makes the
delivery system more rigid than the CP, it provides a smaller
contact surface, which may reduce thrombogenicity and the
risk of venous occlusion.
The CP (Microvention, Terumo, Tustin, CA, USA) is
a self-expanding, braided, nitinol stent with a dual-layer
micromesh design, originally developed to treat patients
with carotid artery stenosis [23]. Its inner layer has small
cells measuring 375–500µm, which are meant to reduce the
risk of plaque prolapse and embolic release [24]. The nitinol
material, the braided structure and the low profile provide
a high level of flexibility and crossability allowing the stent
to adapt to tortuous vessel anatomy without being prone to
kinking [24]. The CP can be resheathed and repositioned
after up to 50% deployment, which enables a more accurate
device placement.
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Headache intensity (VAS) 80.0% (12/15) 7.25 (5.88–9.0) 8.75 (7.13–9.38) 6.25 (1.38–7.0) 0.048a
Headache frequency (per week) 80.0% (12/15) 7 (5.13–7) 7 (5.13–7) 7 (1.8–7) 0.933
≤1 – 13.4% (2) 10.0% (1) 20.0% (1) –
2–4 – 0.0% (0) 0.0% (0) 0.0% (0) –
>4 – 66.7% (10) 70.0% (7) 60.0% (3) –
Presence of more than one type of
headache
80.0% (12/15) 46.7% (7) 40.0% (4) 60.0% (3) 0.576
Other symptoms/findings
Nausea/vomiting 100% (15/15) 66.7 (10/15) 80.0% (8) 40.0% (2) 0.251
Photophobia/phonophobia 100% (15/15) 26.7% (4/15) 30.0% (3) 20.0% (1) 1.000
Tinnitus 100% (15/15) 60.0% (9/15) 50.0% (5) 80.0% (4) 0.580
Diplopia 100% (15/15) 20.0% (3/15) 20.0% (2) 20.0% (1) 1.000
Visual disturbances 100% (15/15) 73.3% (11/15) 60.0% (6) 100% (5) 0.231
Papilledema 100% (15/15) 66.7% (10/15) 60.0% (6) 80.0% (4) 0.600
Daily life impairment 80.0% (12/15) 80.0% (12/15) 80.0% (8/10) 80.0% (4/5) *
Symptom duration (months) 100% (15/15) 23.6
(4.73–61.67)
26.9 (3.92–102.85) 12 (5.47–170.09) 0.953
Treatment before VSS
Conservative treatment 100% (15/15) 93.3% (14/15) 90.0% (9) 100% (5) 1.000
Duration of conservative treat-
ment (months)
100% (15/15) 18 (6–23) 18.5 (6.0–24.5) 7 (6–27) 0.679
Surgical treatment 100% (15/15) 6.7% (1/15) 0.0% (0) 20.0% (1) 0.333
Pressure values
CSF OP (cmH20) 86.7% (13/15) 31 (24–43.5) 35 (26.0–49.5) 27 (23.0–36.25) 0.414




23 (8.5–26.25) 21.5 (17.75–31.25) 0.733
TSPG immediately before stent-
ing in GA (mmHg)
100% (15/15) 10 (7–19) 8.5 (2.5–12) 19 (8.5–39) 0.099
CSF OP cerebral spinal fluid opening pressure, GA general anesthesia, LA local anesthesia, TSPG transstenotic pressure gradient, VAS visual
analogue scale, VSS venous sinus stenting
* No p-value as only one variable is present
Follow-up at 6Months and Outcome
The DSA, VSM and diagnostic lumbar puncture for CSF
OP measurement were repeated under LA at the 6-month
follow-up. In addition to chart review, patients were in-
terviewed at least 6 months after VSS to assess improve-
ment of all IIH-related symptoms as well as quality of daily
life (see Supplementary form A). Patients were also asked
about their symptoms prior to VSS. Their statements were
compared to the information acquired from chart review.
The interval between VSS and the last clinical follow-
up was documented for each patient. Evolution and de-
velopment of papilledema was assessed by reviewing oph-
thalmology reports. Postinterventional magnetic resonance
imaging (MRI) and clinical charts were checked for any
signs of intracranial hemorrhage, venous infarction or other
signs of postinterventional complications.
Statistical Analysis
Data analysis was performed using SPSS Software (Ver-
sion 25.0, IBM Analytics, Armonk, NY, USA). Continuous
variables were compared using the Mann-Whitney U-test,
whereas categorical variables were compared with Fischer’s
exact test. Results with two-tailed p-values of <0.05 were
considered statistically significant and are shown as median
(interquartile range 25–75%), median comparisons with p-
values according to applied test or total values (n).
Results
Between October 2016 and April 2020 there were 15 fe-
male patients (mean ag: 28.7 years, range 24.0–41.5 years)
diagnosed with IIH who underwent VSS for venous si-
nus stenosis at Bern University Hospital. There were no
K
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Headache intensity (VAS) 80.0% (12/15) 0 (0–0) 0 (0–0) 0 (0–1.13) 0.808
Headache intensity improvement
(VAS)
80.0% (12/15) –7 (–8.88 to
–4.13)
–8 (–9.38 to –5.13) –5.5 (–7 to –1) 0.109
Headache frequency (per week) 80.0% (12/15) 0 (0–0) 0 (0–0) 0 (0–0) 0.808
≤1 – 73.3% (11) 70.0% (7) 80.0% (4) –
2–4 – 6.7% (1) 10.0% (1) 0.0% (0) –
>4 – 0.0% (0) 0.0% (0) 0.0% (0) –
Headache frequency improvement
(per week)
80.0% (12/15) –7 (–7 to –4.63) –7 (–7 to –4.63) –7 (–7 to –1.78) 0.933
Improvement of other symptoms/findings among affected
Nausea/vomiting 100% (10/10) 100% (10/10) 100% (8/8) 100.0% (2/2) *
Photophobia/phonophobia 100% (4/4) 100% (4/4) 100% (3/3) 100.0% (1/1) *
Tinnitus 100% (9/9) 77.8% (7/9) 100% (5/5) 50.0% (2/4) 0.073
Diplopia 100% (3/3) 100% (3/3) 100% (2/2) 100.0% (1/1) *
Visual disturbances 100% (11/11) 90.9% (10/11) 100% (6/6) 80.0% (4/5) 0.251
Papilledema 90.0% (9/10) 90.0% (9/10) 83.3% (5/6) 100.0% (4/4) 0.153
Substantial improvement of daily
life
80.0% (12/15) 100% (12/12) 100% (8/8) 100.0% (4/4) *
Follow-up period (months) 80.0% (12/15) 16.6 (7.0–31.4) 11.5 (5.4–28.4) 30.47 (11.79–39.22) 0.206
Pressure values and pressure value improvement
CSF OP (cmH20) 80.0% (12/15) 21.0
(16.25–27.5)
22.0 (16.5–29.5) 20 (15–**) 0.373
CSF OP improvement (cmH20) 80.0% (12/15) –11 (–24 to
–6.5)
–12 (–27.5 to –5.5) –10 (–18–**) 1.000
TSPG immediately after stenting
(mmHg)
100% (15/15) 1 (0–3) 1 (0.75–2.25) 1 (0–5.5) 0.953
TSPG improvement immediately
after stenting (mmHg)
100% (15/15) –8 (–19 to –5) –8 (–10.25 to
–1.75)
–19 (–35.5 to –6) 0.165
TSPG at 6 months follow-up
(mmHg)
93.3% (14/15) 1 (0–5) 1.5 (0.75–5) 0.5 (0–5.5) 0.454
TSPG improvement at 6 months
follow-up (mmHg)




–21 (–26 to –17.5) 0.304
CSF OP cerebral spinal fluid opening pressure, GA general anesthesia, LA local anesthesia, TSPG transstenotic pressure gradient, VAS visual
analogue scale, VSS venous sinus stenting
* No p-value as only one variable is present, ** no 75% percentile
differences in demographic characteristics or comorbidities
between patients treated with the CP (n= 10) and the PP
(n= 5) (Table 1). One patient who was scheduled to receive
the PP was ultimately treated with the CP due to failure of
delivery of the PP. For the purpose of comparing postin-
terventional outcome parameters, this patient was included
in the CP group. Prior to VSS, 14 patients had been man-
aged conservatively and 1 patient (n= 1/15; in the PP group)
underwent surgery (ventriculoperitoneal shunt). Mean du-
ration of conservative treatment tended to be longer but not
statistically significantly different for patients treated with
the CP than for patients who received the PP (18.5 months
versus 7 months; p= 0.679). All venous stenoses treated
were located in the lateral segment of the transverse sinus
or the transverse-sigmoid junction. Symptoms and pressure
values before and after VSS are summarized in Tables 2
and 3.
Difficulty of Stent Delivery and Technical Outcome
Stent delivery was easier and more successful with the CP
than with the PP (difficult or failed stent delivery 0.0%
versus 57.1%). The number of attempts was lower in the
CP than in the PP group (≥2: 0.0% versus 40.0%). Ad-
ditional balloon dilatation due to residual stenosis was re-
quired in 3/10 CP patients and in 2/5 PP patients (30% ver-
sus 40%). No periinterventional complications were noted
during VSS. None of the patients showed stent thrombo-
K
N. F. Belachew et al.
Table 4 Difficulty of stent delivery and periinterventional and postinterventional outcome parameters. Data are expressed as percentages (n)





Difficulty of stent delivery (per attempt) 100% (17/17) – – –
Easy – 76.5% (13/17) 100% (10/10) 42.9% (3/7)
Difficult or failed – 23.5% (4/17) 0.0% (0/10) 57.1% (4/7)
Attempts (per patient) 100% (15/15) – – –
<2 – 86.7% (13/15) 100% (10/10) 60.0% (3/5)
≥2 – 13.3% (2/15) 0.0% (0/10) 40% (2/5)
Other outcome parameters – – – –
Additional balloon dilatation applied due to residual stenosis 100% (15/15) 33.3% (5/15) 30.0% (3) 40.0% (2)
Symptomatic intracranial hemorrhage 100% (15/15) 0.0% (0/15) 0.0% (0/10) 0.0% (0/5)
Venous infarction 100% (15/15) 0.0% (0/15) 0.0% (0/10) 0.0% (0/5)
Other complications 100% (15/15) 6.7% (1/15) 0.0% (0/10) 20.0% (1/5)
sis, venous occlusion or stenosis requiring retreatment at
6-month follow-up. Interventional characteristics are listed
in Table 4. Figures 1 and 2 show the successful deployment
of the CP and the PP in IIH patients with venous sinus
stenosis.
Headache Before and After VSS
Four of 10 patients later treated with the CP and 3 of 5 pa-
tients who received the PP complained of multiple types
of headaches before the intervention [20] (40.0% versus
60.0%; p= 0.408). Headache intensity was initially signif-
icantly higher among patients treated with the CP (VAS
8.75 versus 6.25, p= 0.048), whereas headache frequency
before VSS was similar in the two groups (CP versus PP;
7 times per week versus 7 times per week, p= 0.933). Pa-
tients in both groups showed a substantial but similar reduc-
tion of headache intensity (CP versus PP; headache VAS af-
ter VSS: 0 versus 0, p= 0.808; headache VAS improvement
after VSS: –8 versus –5.5, p= 0.087). Headache frequency
also decreased in both groups (CP versus PP; headache
frequency after VSS: 0 versus 0, p= 0.808; headache fre-
quency improvement after VSS: –7 times per week versus
–7 times per week, p= 0.920) after VSS.
Other IIH-related Symptoms Before and After VSS
All patients included in this study had additional IIH-related
symptoms of which visual disturbances (n= 11/15; 73.3%),
nausea/vomiting (n= 10/15; 66.7%) and tinnitus (n= 10/15;
66.7%) were the most frequent. Papilledema was docu-
mented in 6/10 patients treated with the CP and 4/5 treated
with PP (60.0% versus 80.0%; p= 0.439). All patients who
were available for interview 6 months after VSS (n= 12/15;
80.0%) reported substantial impairment of daily life be-
fore VSS, which they attributed to the restraints imposed
by IIH. Symptom duration prior to any treatment tended to
be longer but was not significantly different between pa-
tients treated with the CP and the PP (26.9 months versus
12 months; p= 0.953). All patients who reported nausea/
vomiting (n= 10/10), photophobia/phonophobia (n= 4/4) or
diplopia (n= 3/3) showed substantial improvement or com-
plete cessation of these complaints after VSS. Almost all
patients who had tinnitus (n= 7/9; CP versus PP: 100%
versus 50.0%, p= 0.073) or visual disturbances other than
diplopia (n= 10/11; CP versus PP: 100% versus 80.0%,
p= 0.250) reported substantial improvement or complete
cessation of those symptoms. All patients with papilledema
who were available for follow-up (n= 8/9) showed substan-
tial or complete resolution on ophthalmological examina-
tion. A substantial improvement in quality of life after VSS
was reported by all patients who were available for inter-
view (n= 12/15).
Pressure Values Before and After VSS
No significant differences in CSF OP for patients treated
with CP versus PP before (35 cmH20 versus 27 cmH20;
p= 0.414) and after VSS (22.0cmH20 versus 20cmH20,
p= 0.373) were found. Similarly, TSPG under LA and GA
before (TSPG under LA: 23mmHg versus 21.5mmHg,
p= 0.733; TSPG under GA: 8.5mmHg versus 19mmHg,
p= 0.099) and after VSS (TSPG in LA: 1.5mmHg ver-
sus 0mmHg, p= 0.454; TSPG in GA: 1mmHg versus
1mmHg, p= 0.953) were not significantly different be-
tween the CP and PP groups. Both stents achieved notable
and comparable reduction of CSF OP (–12cmH20 ver-
sus–10cmH20, p= 1.000), TSPG under LA (–19mmHg ver-
sus –21mmHg, p= 0.304) and TSPG under GA (–8mmHg
versus –19mmHg, p= 0.165).
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Fig. 1 a Shows the digital sub-
traction angiography (DSA) of
a patient who has idiopathic
intracranial hypertension with
a long extrinsic venous sinus
stenosis involving the right
transverse sinus and the proxi-
mal sigmoid sinus. The images
that follow show the advanc-
ing (b) and subsequent de-
ployment (c) of a CasperTM
carotid stent (10× 30mm) across
the stenosis without difficulty.
The control angiography after
stent deployment (d) shows no





No patients in either group had any new neurological
deficits, symptomatic intracranial hemorrhage or venous
infarction after VSS. One patient who received the PP
developed an abscess at the puncture site of the femoral
arterial access, which led to sepsis. The patient was treated
with antibiotics and recovered well. The interval between
VSS and last clinical follow-up tended to be longer in the PP
group, but this difference was not significant (17.1 months
versus 31.7 months, p= 0.126).
Discussion
The main findings of this study were: (1) stent delivery
was easier and more successful with the CP than with the
PP. (2) No severe periinterventional or postinterventional
complications occurred in either group. (3) None of the pa-
tients showed stent thrombosis, venous occlusion or steno-
sis requiring retreatment at 6-month follow-up. (4) The CSF
OP, TSPG improvement immediately after VSS and TSPG
6 months after stenting were similar in the CP and the PP
group. (5) Both groups showed substantial and comparable
reduction of headache intensity and frequency after VSS.
(6) Almost all patients who had other IIH-related symp-
toms showed either improvement or complete cessation of
the complaints after VSS, resulting in a comparable and
substantial improvement in daily life.
To the best of our knowledge this is the first study to ex-
amine the benefits of using the CP for VSS in IIH patients
who have venous sinus stenosis. It is also the first attempt to
compare different stent types used for VSS with respect to
difficulty of delivery, technical and clinical outcome as well
as complication rates [17]. Our data support the hypothe-
sis that stent-specific characteristics influence the technical
success of stent delivery.
Navigating the intracranial venous system and crossing
the venous stenosis for safe stent delivery may be challeng-
ing for several reasons. These include the tortuosity of the
transverse and sigmoid sinuses, the high degree of stenosis,
the angle of the stenotic segment, small venous channels
within the sinus, arachnoid granulations, fibrous trabeculae
or the presence of a cortical vein draining into the dural si-
nus, which are frequently observed in IIH patients [10–13].
Inability to advance the stent system beyond the venous
stenosis can result in failure of the procedure.
Several endovascular techniques that may help to man-
age these challenging circumstances have been reported.
For example, using stiffer microwires and microcatheters
combined with an increased forward pressure to the catheter
system may lead to technical success; however, forceful de-
vice maneuvers, especially in patients on antiplatelet ther-
apy, can lead to severe hemorrhagic complications due to
avulsion of cortical veins, dissection or perforation of the
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Fig. 2 a Shows the digital sub-
traction angiography (DSA) of
a patient who has idiopathic
intracranial hypertension with
an extrinsic stenosis of the right
transverse sinus that has gen-
erated a transstenotic pressure
gradient of 24mmHg measured
by venous sinus manometry.
Advancing the Precise Pro RX
carotid stent (9× 40mm) turned
out to be difficult owing to the
kinked anatomy of the sigmoid
sinus and the stiffness of the
stent system (b). Successful
stent delivery was only achieved
after advancing an 8F Guider
Softip over a Vasco +35 in-
termediate catheter through an
8F arrow sheath into the trans-
verse sinus. c Shows residual





sinus [14–16]. The rising number of IIH patients being
treated with VSS means that the probability of encoun-
tering these relatively rare complications may increase too.
Intracranial hemorrhages resulting from venous or cortical
vein injury are particularly difficult to treat and may cause
severe morbidity or even death. Choosing the best tech-
niques and applying appropriate materials may decrease the
risk of these complications. Schwarz et al. [10] described
the cobra technique as favorable when navigation and/or ad-
vancement of an intermediate catheter beyond the stenosis
requires increased loading of the system: A 3.5mm bal-
loon is advanced through the intermediate catheter to the
level of the stenosis and inflated below the balloon’s nom-
inal pressure. The intermediate catheter is then advanced
in close proximity to the proximal end of the balloon plac-
ing it partially within the intermediate catheter. Finally, the
balloon and intermediate catheter can be advanced together
over the microwire and beyond the stenotic segment. Gor-
don et al. [11] described transverse-sigmoid sinus stenting
from the contralateral dural sinus as an alternative to the
typical antegrade approach. This seems to be advantageous
in the case of a high-grade stenosis or whenever the angle at
which the tip of the stent delivery catheter entered the trans-
verse sinus prevents advancement of the stent system in an
antegrade way. Delivering the stent from the contralateral
side changes the angle of entry and may allow advancement
of the stent without injuring the vessel wall; however, this
approach is only possible in patients with a contralateral si-
nus that is large enough to accommodate the stent delivery
system and a superior sagittal sinus bifurcation that is not
too high. Thus, stent delivery systems that could provide
better navigability and flexibility may improve the chances
of technically successful VSS.
The unique flexibility of the CP makes it particularly
suitable for patients with tortuous intracranial venous
anatomy; however, the inverse relationship between device
flexibility and radial force is a limiting factor that needs to
be considered to guarantee long-term stent patency [25].
Despite concerns about increased thrombogenicity caused
by the CP’s larger contact surface, no venous thrombosis,
occlusion or infarction was observed in any of the patients.
Its low-profile delivery system provides better crossabil-
ity, making lesions and tortuous vessel segments more
accessible for interventional maneuvering.
Leishangthem et al. [17] reported that the stents most fre-
quently used for VSS are the PP and the Carotid WallstentTM
(Boston Scientific, Marlborough, MA, USA). Although the
challenges of safe stent delivery are well-known [10], many
studies do not mention the rationale for stent selection nor
do they identify the particular stents chosen [17, 22]. Fur-
ther research is required to define stent characteristics ben-
eficial for the treatment of venous sinus stenosis in patients
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with IIH. The development of IIH-specific stents could im-
prove technical efficacy of VSS. Ultimately this would help
to avoid aggressive maneuvers that could lead to severe
complications [14–16] and increase the number of patients
showing sustainable long-term improvement after VSS.
Our data also underline the safety and efficacy of VSS
in IIH patients with venous sinus stenosis [4–9]. Other than
VSS, few treatment options are available for patients who
do not respond adequately to conservative treatment [18].
The VSS has proven to be a safe and efficient alterna-
tive that does not seem to be inferior to surgical treatment
methods [3, 26]. Given the young age of patients with IIH,
VSS constitutes an appealing treatment option that promises
a good chance of symptom improvement and an excellent
outcome.
The reduction of CSF OP and TSPG after VSS, fol-
lowed by a substantial improvement of IIH-related symp-
toms, suggest that changes in intracranial venous pressure
play a central role in the pathomechanisms causing IIH-re-
lated symptoms and may help categorize IIH patients based
on objective phenotypes [26–28]. Although IIH genesis is
not yet fully understood, the regulation of intracranial ve-
nous pressure achieved by VSS seems to offer an effective
approach for treatment of the wide spectrum of IIH-related
symptoms.
Limitations
This was a retrospective, monocentric study, which may
limit generalizability. Only 15 patients were included,
which could have led to sampling error. All data presented
in this study were gathered either by extensive chart review
and/or patient interviews; however, some patients were re-
ferred by external physicians who could not always provide
the information required for our analysis. Documentation
of clinical information before and after stenting was not
standardized and was performed by different departments.
In some instances, patient interviews were conducted up
to 3.75 years after VSS. Thus, results on symptom im-
provement are prone to recall bias as some patients may
overestimate or underestimate symptoms prior to VSS.
As symptom improvement is limited by initial severity
and almost all patients reported substantial improvement
or complete resolution of IIH-related symptoms, correla-
tion analyses between symptom improvement and duration
of the follow-up period were not informative. Some pa-
tients were lost to follow-up causing further data gaps and
potential selection bias. Like any symptoms, IIH-related
complaints and daily life impairment are subjective and
hard to quantify. Hence, headache was the only symptom
to be quantified using the VAS.
Conclusion
We observed that the CASPERTM carotid stent is a safe
and effective alternative for the treatment of venous sinus
stenosis in IIH patients that do not respond to conserva-
tive treatment. It may reduce the risk of difficult or failed
stent delivery in patients with challenging intracranial ve-
nous anatomy. Our findings underline the need for dedicated
stent systems that are adapted to the tortuous intracranial
venous anatomy frequently observed in IIH patients requir-
ing treatment for venous sinus stenosis.
Supplementary Information The online version of this article (https://
doi.org/10.1007/s00062-021-01024-2) contains supplementary mate-
rial, which is available to authorized users.
Acknowledgements We thank Susan Kaplan for editorial assistance.
Funding Open Access funding provided by Universität Bern.
Conflict of interest N. F. Belachew, S. Baschung, W. Almiri, R. Enci-
nas, J. Kaesmacher, T. Dobrocky, C. J. Schankin, M. Abegg,
E. I. Piechowiak, A. Raabe, J. Gralla and P. Mordasini declare that
they have no competing interests.
Open Access This article is licensed under a Creative Commons At-
tribution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article’s Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included
in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view
a copy of this licence, visit http://creativecommons.org/licenses/by/4.
0/.
References
1. Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding id-
iopathic intracranial hypertension: Mechanisms, management, and
future directions. Lancet Neurol. 2016;15:78–91.
2. Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE,
Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP;
NORDIC Idiopathic Intracranial Hypertension Study Group. The
idiopathic intracranial hypertension treatment trial: clinical profile
at baseline. JAMA Neurol. 2014;71:693–701.
3. Nicholson P, Brinjikji W, Radovanovic I, Hilditch CA, Tsang ACO,
Krings T, Mendes Pereira V, Lenck S. Venous sinus stenting for
idiopathic intracranial hypertension: a systematic review and meta-
analysis. J Neurointerv Surg. 2019;11:380–5.
4. Puffer RC, Mustafa W, Lanzino G. Venous sinus stenting for idio-
pathic intracranial hypertension: a review of the literature. J Neu-
rointerv Surg. 2013;5:483–6. https://doi.org/10.1136/neurintsurg-
2012-010468
5. Shields LBE, Shields CB, Yao TL, Plato BM, Zhang YP, Dashti SR.
Endovascular Treatment for Venous Sinus Stenosis in Idiopathic In-
tracranial Hypertension: An Observational Study of Clinical Indica-
tions, Surgical Technique, and Long-Term Outcomes. World Neu-
rosurg. 2019;121:e165–71.
K
N. F. Belachew et al.
6. Dinkin MJ, Patsalides A. Venous sinus stenting in idiopathic In-
tracranial hypertension: results of a prospective trial. J Neurooph-
thalmol. 2017;37:113–21.
7. Patsalides A, Oliveira C, Wilcox J, Brown K, Grover K, Gobin YP,
Dinkin MJ. Venous sinus stenting lowers the intracranial pressure
in patients with idiopathic intracranial hypertension. J Neurointerv
Surg. 2019;11:175–8.
8. Al-Mufti F, Dodson V, Amuluru K, Walia J, Wajswol E, Nuoman
R, Keller IA, Schonfeld S, Roychowdhury S, Gupta G. Neuroen-
dovascular Cerebral Sinus Stenting in Idiopathic Intracranial Hy-
pertension. Interv Neurol. 2020;8:164–71.
9. Touzé R, Bonnin S, Houdart E, Nicholson P, Bodaghi B, Shotar E,
Clarençon F, Lenck S, Touitou V. Long-term kinetic papilledema
improvement after venous sinus stenting in idiopathic intracra-
nial hypertension. Clin Neuroradiol. 2020. https://doi.org/10.1007/
s00062-020-00908-z
10. Schwarz J, Santillan A, Patsalides A. Safely traversing venous si-
nus stenosis: The “Cobra” technique. Interv Neuroradiol. 2020;26:
231–4.
11. Gordon W, Abraham M. Contralateral approach to transverse-sig-
moid sinus stenting. Interv Neuroradiol. 2020;26:658–63.
12. Schwarz J, Al Balushi A, Sundararajan S, Dinkin M, Oliveira
C, Greenfield JP, Patsalides A. Management of idiopathic in-
tracranial hypertension in children utilizing venous sinus stent-
ing. Interv Neuroradiol. 2021;27:257–65. https://doi.org/10.1177/
1591019920976234
13. McCormick MW, Bartels HG, Rodriguez A, Johnson JE, Jan-
jua RM. Anatomical variations of the transverse-sigmoid sinus
junction: implications for endovascular treatment of idiopathic
Intracranial hypertension. Anat Rec. 2016;299:1037–42.
14. Kumpe DA, Bennett JL, Seinfeld J, Pelak VS, Chawla A, Tier-
ney M. Dural sinus stent placement for idiopathic intracranial hy-
pertension: clinical article. J Neurosurg. 2012;116:538–48.
15. Ahmed RM, Wilkinson M, Parker GD, Thurtell MJ, Macdonald J,
McCluskey PJ, Allan R, Dunne V, Hanlon M, Owler BK, Halmagyi
GM. Transverse sinus stenting for idiopathic intracranial hyperten-
sion: a review of 52 patients and of model predictions. AJNR Am J
Neuroradiol. 2011;32:1408–14. https://doi.org/10.3174/ajnr.A2575
16. Lavoie P, Audet MÈ, Gariepy JL, Savard M, Verreault S, Gourdeau
A, Milot G, Carrondo Cottin S. Severe cerebellar hemorrhage fol-
lowing transverse sinus stenting for idiopathic intracranial hyper-
tension. Interv Neuroradiol. 2018;24:100–5.
17. Leishangthem L, SirDeshpande P, Dua D, Satti SR. Dural venous
sinus stenting for idiopathic intracranial hypertension: An updated
review. J Neuroradiol. 2019;46:148–54.
18. Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF di-
version procedures and dural venous sinus stenting in the setting
of medically refractory idiopathic intracranial hypertension. AJNR
Am J Neuroradiol. 2015;36:1899–04.
19. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the
pseudotumor cerebri syndrome in adults and children. Neurology.
2013;81:1159–65.
20. Olesen J. Headache Classification Committee of the Interna-
tional Headache Society (IHS) The International Classification of
Headache Disorders. 3rd ed. Cephalalgia: SAGE; 2018. pp. 1–211.
21. Fargen KM, Spiotta AM, Hyer M, Lena J, Turner RD, Turk AS,
Chaudry I. Comparison of venous sinus manometry gradients ob-
tained while awake and under general anesthesia before venous si-
nus stenting. J Neurointerv Surg. 2017;9:990–3.
22. Fargen KM, Liu K, Garner RM, Greeneway GP, Wolfe SQ, Crow-
ley RW. Recommendations for the selection and treatment of
patients with idiopathic intracranial hypertension for venous sinus
stenting. J Neurointerv Surg. 2018;10:1203–8.
23. Mutzenbach SJ, Millesi K, Roesler C, Broussalis E, Pikija S, Sell-
ner J, Machegger L, Griessenauer CJ, Killer-Oberpfalzer M. The
Casper Stent System for carotid artery stenosis. J Neurointerv Surg.
2018;10:869–73.
24. Diaz O, Lopez G, Roehm JOF Jr, De la Rosa G, Orozco F, Almeida
R. The Casper carotid artery stent: a unique all metal micromesh
stent designed to prevent embolic release. J Neurointerv Surg.
2018;10:133–6.
25. Müller MD, Gregson J, McCabe DJH, Nederkoorn PJ, van der
Worp HB, de Borst GJ, Cleveland T, Wolff T, Engelter ST, Lyrer
PA, Brown MM, Bonati LH. Stent design, restenosis and recur-
rent stroke after carotid artery stenting in the international carotid
stenting study. Stroke. 2019;50:3013–20.
26. Gurney SP, Ramalingam S, Thomas A, Sinclair AJ, Mollan SP. Ex-
ploring The Current Management Idiopathic Intracranial Hyperten-
sion, And Understanding The Role Of Dural Venous Sinus Stenting.
Eye Brain. 2020;12:1–13. https://doi.org/10.2147/EB.S193027
27. Fargen KM. Idiopathic intracranial hypertension is not idiopathic:
proposal for a new nomenclature and patient classification. J Neu-
rointerv Surg. 2020;12:110–4. https://doi.org/10.1136/neurintsurg-
2019-015498
28. Fargen KM, Garner RM, Kittel C, Wolfe SQ. A descriptive study
of venous sinus pressures and gradients in patients with idiopathic
intracranial hypertension. J Neurointerv Surg. 2020;12:320–5.
K
